Raj Satkunasivam, MD, MS, FRCSC

GU Oncology Now

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, shares how sasanlimab has shown a favorable toxicity profile in phase 1 data, which subsequently has led to a phase 3 trial combining the immune checkpoint inhibitor with bacillus Calmette-Gu&eacute;rin (BCG) concurrently in patients with high-risk, BCG-na&iuml;ve non-muscle invasive bladder cancer (NMIBC).The encouraging results of this trial led to the formation of the <a href="https://guoncologynow.com/post/dr-raj-satkunasivam-on-mibc-neoadjuvant-approaches-for-local-distant-control" target="_blank" rel="noopener">RAD VACCINE MIBC trial</a>, a phase 2 assessment of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC.<a href="https://guoncologynow.com/post/dr-raj-satkunasivam-on-neoadjuvant-sasanlimab-and-sbrt-for-cisplatin-ineligible-mibc" target="_blank" rel="noopener">Hear what else</a> Dr. Satkunasivam has to say about the phase 2 trial.

How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?

Non-Muscle Invasive Urothelial Carcinoma

Dr. Satkunasivam shares the inspiration for a phase 3 trial combining sasanlimab with BCG concurrently in patients with high-risk, BCG-naïve NMIBC.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe